全文获取类型
收费全文 | 48939篇 |
免费 | 3575篇 |
国内免费 | 2468篇 |
专业分类
耳鼻咽喉 | 254篇 |
儿科学 | 1363篇 |
妇产科学 | 473篇 |
基础医学 | 11254篇 |
口腔科学 | 387篇 |
临床医学 | 3673篇 |
内科学 | 13562篇 |
皮肤病学 | 581篇 |
神经病学 | 1216篇 |
特种医学 | 620篇 |
外国民族医学 | 7篇 |
外科学 | 2110篇 |
综合类 | 6305篇 |
现状与发展 | 18篇 |
预防医学 | 7372篇 |
眼科学 | 392篇 |
药学 | 2469篇 |
13篇 | |
中国医学 | 853篇 |
肿瘤学 | 2060篇 |
出版年
2024年 | 47篇 |
2023年 | 611篇 |
2022年 | 1866篇 |
2021年 | 2153篇 |
2020年 | 1703篇 |
2019年 | 1489篇 |
2018年 | 1501篇 |
2017年 | 1470篇 |
2016年 | 1741篇 |
2015年 | 2044篇 |
2014年 | 2831篇 |
2013年 | 3005篇 |
2012年 | 2767篇 |
2011年 | 3254篇 |
2010年 | 2685篇 |
2009年 | 2452篇 |
2008年 | 2398篇 |
2007年 | 2531篇 |
2006年 | 2271篇 |
2005年 | 1997篇 |
2004年 | 1761篇 |
2003年 | 1534篇 |
2002年 | 1222篇 |
2001年 | 1185篇 |
2000年 | 961篇 |
1999年 | 861篇 |
1998年 | 754篇 |
1997年 | 770篇 |
1996年 | 627篇 |
1995年 | 631篇 |
1994年 | 594篇 |
1993年 | 473篇 |
1992年 | 354篇 |
1991年 | 302篇 |
1990年 | 269篇 |
1989年 | 244篇 |
1988年 | 231篇 |
1987年 | 167篇 |
1986年 | 142篇 |
1985年 | 287篇 |
1984年 | 181篇 |
1983年 | 134篇 |
1982年 | 120篇 |
1981年 | 98篇 |
1980年 | 68篇 |
1979年 | 58篇 |
1978年 | 51篇 |
1977年 | 31篇 |
1976年 | 31篇 |
1975年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文
2.
《Vaccine》2016,34(26):2948-2952
Herpes simplex virus type-1 (HSV-1) and -2 (HSV-2) are highly prevalent global pathogens which commonly cause recurrent oral and genital ulcerations. Less common but more serious complications include meningitis, encephalitis, neonatal infection, and keratitis. HSV-2 infection is a significant driver of the HIV epidemic, increasing the risk of HIV acquisition 3 fold. As current control strategies for genital HSV-2 infection, including antiviral therapy and condom use, are only partially effective, vaccines will be required to reduce infection. Both preventive and therapeutic vaccines for HSV-2 are being pursued and are in various stages of development. We will provide an overview of efforts to develop HSV-2 vaccines, including a discussion of the clinical need for an HSV vaccine, and status of research and development with an emphasis on recent insights from trials of vaccine candidates in clinical testing. In addition, we will touch upon aspects of HSV vaccine development relevant to low and middle income countries. 相似文献
3.
Frédéric Janvier Deborah Delaune Thomas Poyot Eric Valade Audrey Mérens Pierre E. Rollin Vincent Foissaud 《Emerging infectious diseases》2016,22(2):292-294
We evaluated RNA stability of Ebola virus in EDTA blood and urine samples collected from infected patients and stored in West Africa’s environmental conditions. In blood, RNA was stable for at least 18 days when initial cycle threshold values were <30, but in urine, RNA degradation occurred more quickly. 相似文献
4.
5.
6.
7.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
8.
《Vaccine》2016,34(8):1115-1125
Chronic hepatitis C virus (HCV) infection represents a major health threat to global population. In India, approximately 15–20% of cases of chronic liver diseases are caused by HCV infection. Although, new drug treatments hold great promise for HCV eradication in infected individuals, the treatments are highly expensive. A vaccine for preventing or treating HCV infection would be of great value, particularly in developing countries. Several preclinical trials of virus-like particle (VLP) based vaccine strategies are in progress throughout the world. Previously, using baculovirus based system, we have reported the production of hepatitis C virus-like particles (HCV-LPs) encoding structural proteins for genotype 3a, which is prevalent in India. In the present study, we have generated HCV-LPs using adenovirus based system and tried different immunization strategies by using combinations of both kinds of HCV-LPs with other genotype 3a-based immunogens. HCV-LPs and peptides based ELISAs were used to evaluate antibody responses generated by these combinations. Cell-mediated immune responses were measured by using T-cell proliferation assay and intracellular cytokine staining. We observed that administration of recombinant adenoviruses expressing HCV structural proteins as final booster enhances both antibody as well as T-cell responses. Additionally, reduction of binding of VLP and JFH1 virus to human hepatocellular carcinoma cells demonstrated the presence of neutralizing antibodies in immunized sera. Taken together, our results suggest that the combined regimen of VLP followed by recombinant adenovirus could more effectively inhibit HCV infection, endorsing the novel vaccine strategy. 相似文献
9.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C 下载免费PDF全文
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
10.
D Gröne† R Treudler† EM de Villiers‡ R Husak† CE Orfanos† ChC Zouboulis†§ 《Journal of the European Academy of Dermatology and Venereology》2006,20(2):202-205
Cidofovir is an acyclic nucleoside phosphonate with broad-spectrum activity against DNA viruses, including human papilloma virus (HPV). However, data on the efficacy of cidofovir in an immunosuppressive setting remain contradictory. We report for the first time on the promotion of the healing of recalcitrant warts in a patient with myelodysplastic syndrome with intravenous cidofovir treatment. 相似文献